EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and safety of immune checkpoint inhibitors in advanced or recurrent endometrial cancer: individual patient data and trial-level meta-analysis

Fengping Shao, Yanchun Liang

Journal of Gynecologic Oncology · 2027 · 38

DOI: 10.3802/jgo.2027.38.e46 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Gynecologic Oncology, 2027. Verfasst von Fengping Shao und 1 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province, First Affiliated Hospital of Sun Yat-sen University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective Whether immune checkpoint inhibitor (ICI)-based regimens confer a survival benefit over chemotherapy (CT) alone in advanced/recurrent endometrial cancer (EC), particularly by mismatch repair status, remains inconclusive. We conducted an individual patient data (IPD) meta-analysis of randomized trials comparing ICI-based regimens vs. CT alone to quantify survival benefits and assess safety.

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Guangdong Province
  • First Affiliated Hospital of Sun Yat-sen University

Zitieren

APA

Shao, F., & Liang, Y. (2027). Efficacy and safety of immune checkpoint inhibitors in advanced or recurrent endometrial cancer: individual patient data and trial-level meta-analysis. Journal of Gynecologic Oncology, 38. https://doi.org/10.3802/jgo.2027.38.e46

Vancouver

Shao F, Liang Y. Efficacy and safety of immune checkpoint inhibitors in advanced or recurrent endometrial cancer: individual patient data and trial-level meta-analysis. Journal of Gynecologic Oncology. 2027;38. doi:10.3802/jgo.2027.38.e46

BibTeX
@article{Shao2027,
  author = {Shao, Fengping and Liang, Yanchun},
  title = {Efficacy and safety of immune checkpoint inhibitors in advanced or recurrent endometrial cancer: individual patient data and trial-level meta-analysis},
  journal = {Journal of Gynecologic Oncology},
  year = {2027},
  volume = {38},
  doi = {10.3802/jgo.2027.38.e46}
}
Kostenlos starten →